RxDoctor Payments Data

Malcolm Gottesman, MD

Neurology · Mineola, NYNPI 1083677389

Payments from drug & device makers

$55,381in general payments, 2019–2025

Across 26 payments — averaging $2130.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$36K
  • Biogen$19K
  • EMD Serono, Inc.$94
  • AstraZeneca$59
  • Novartis$48
  • Vanda Pharmaceuticals Inc.$32
  • plus $44 from 2 others

What the payments were for

  • Food & beverage$472100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi16$35,854
Biogen2$19,250
EMD Serono, Inc.1$94
AstraZeneca2$59
Novartis2$48
Vanda Pharmaceuticals Inc.1$32
AbbVie1$31
Amgen1$13

How this compares

$55,381 in reported general payments places this provider in the 80th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$78,875
Medicare patients
218
Services billed
843

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TecfideraDimethyl Fumarate36$373,529
VumerityDiroximel Fumarate43$372,263
Avonex Pen (4 Pack)Interferon Beta-1a42$361,103
MayzentSiponimod29$263,516
Dalfampridine ErDalfampridine163$259,621
Kesimpta PenOfatumumab16$165,811
CopaxoneGlatiramer Acetate27$159,101
Glatiramer Acetate12$84,463
GlatopaGlatiramer Acetate20$70,225
UbrelvyUbrogepant25$51,009
AmpyraDalfampridine11$47,853
HorizantGabapentin Enacarbil18$16,760
Nurtec OdtRimegepant Sulfate12$15,717
NeuproRotigotine12$9,591
Ajovy SyringeFremanezumab-Vfrm11$9,146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera, Vumerity$19,250$745,79279 claims
NovartisMayzent$48$263,51629 claims
AbbVieUbrelvy$31$51,00925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,623 neurology providers in New York.

Other neurology in Mineola

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →